Pulmovant Speeds Hope for Deadly Lung Disease with Rapid Trial Progress

WALTHAM, Mass. – February 06, 2026 – Pulmovant, a subsidiary of Roivant, today announced a significant step forward in the quest for a treatment for a devastating lung condition, completing patient enrollment for a pivotal Phase 2 study in under a year. The trial, named PHocus, is evaluating a potential first-in-class inhaled therapy, mosliciguat, for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with a dire lack of effective treatment options.

The rapid enrollment of approximately 120 participants across the globe highlights the urgent patient need and clinical interest in novel therapies. Pulmovant now anticipates reporting topline results from the study in the second half of 2026, a timeline that could bring a new horizon of hope to a community that has long been underserved.

The Desperate Search for a Breakthrough in PH-ILD

For the estimated 200,000 people living with PH-ILD in the U.S. and Europe, each breath can be a struggle. The disease is a brutal combination of two conditions: interstitial lung disease (ILD), which causes progressive scarring of the lungs, and pulmonary hypertension (PH), which is high blood pressure in the lung's arteries. This dual pathology forces the heart to work dangerously hard, leading to severe shortness of breath, fatigue, and a significantly shortened life expectancy. PH-ILD is considered one of the deadliest forms of pulmonary hypertension.

The therapeutic landscape for these patients is notoriously barren. While numerous treatments exist for other forms of PH, they have often failed or even proven harmful when tested in the PH-ILD population. Past trials for drugs like riociguat and bosentan were stopped due to a lack of efficacy or, in the case of riociguat, an increased risk of death in a subset of patients.

Currently, the only FDA-approved therapy specifically for PH-ILD is inhaled treprostinil. While it offers a proven benefit in exercise capacity, it comes with a high treatment burden, requiring patients to use a nebulizer or inhaler four times per day. This frequent dosing, coupled with side effects like coughing and throat irritation, presents a significant daily challenge for patients already grappling with a debilitating illness. The medical community broadly agrees that the unmet need remains immense, fueling a desperate search for more effective, safer, and more convenient options.

A Differentiated Approach: How Mosliciguat Works

Mosliciguat represents a new strategy in tackling PH-ILD. It is a potential first-in-class, once-daily, inhaled soluble guanylate cyclase (sGC) activator. This mechanism is key to its potential. The drug targets a critical pathway that helps relax and widen blood vessels in the lungs.

What sets mosliciguat apart from earlier drugs like riociguat—an sGC stimulator—is its ability to function in the harsh, oxygen-depleted, and highly oxidative environment characteristic of a scarred lung. Stimulators require the presence of certain molecules to work effectively, molecules that are often lacking in diseased lung tissue. Activators like mosliciguat, however, are designed to work independently, potentially restoring function where stimulators cannot.

This innovative mechanism is delivered directly to the lungs via a dry powder inhaler, designed to maximize its effect where it's needed most while minimizing systemic side effects like low blood pressure that can occur with oral medications. Early data has been highly encouraging. A Phase 1b study in PH patients showed that a single dose of inhaled mosliciguat produced a mean peak reduction in pulmonary vascular resistance (PVR)—a key measure of pressure in the lungs—of up to 38%. This is one of the most significant reductions observed in any PH trial to date, suggesting a potent vasodilatory effect. The convenience of a once-daily dose further positions it as a potentially transformative option for improving quality of life.

Accelerating Hope: The Significance of Rapid Enrollment

Completing enrollment for a rare disease trial in under 12 months is a logistical and clinical feat. The pace of the PHocus study stands as a powerful testament to both the operational execution of the Pulmovant team and the profound demand for new treatments.

“Completing enrollment of the PHocus study in less than one year from first patient dosed underscores the strong demand for new therapeutic options for patients suffering from PH-ILD,” said Drew Fromkin, Chief Executive Officer of Pulmovant, in a statement. “People living with PH-ILD have limited treatment options as current therapies are often poorly tolerated and require multiple doses per day, contributing to a high treatment burden.”

Recruiting for trials in rare diseases is often a slow, arduous process, hampered by small, geographically dispersed patient populations and complex diagnostic criteria. The swift enrollment for PHocus suggests that the promise of mosliciguat—its novel mechanism, promising early data, and convenient dosing schedule—resonated deeply with both patients and the pulmonologists who treat them. The study design, which includes an extension period where all participants will eventually receive the active drug, likely provided an additional incentive for patients to participate, offering them long-term access to a promising investigational therapy.

The 'Vant' Strategy: Roivant's Bet on Specialized Science

Pulmovant’s focused effort on mosliciguat is a textbook example of the strategy employed by its parent company, Roivant Sciences. Roivant operates a unique "Vant" model, creating nimble, specialized subsidiary companies to advance promising drug candidates that may have been deprioritized at larger pharmaceutical firms. Roivant acquired the worldwide rights for mosliciguat from Bayer, betting it could succeed by deploying a dedicated team and resources.

This model allows for deep focus and rapid execution, as demonstrated by Pulmovant's recent milestone. Backed by Roivant's significant financial resources and a track record that includes five FDA approvals and the recent $7.1 billion sale of another 'Vant' company, Pulmovant has the stability and support to see this complex development program through.

By targeting diseases with high unmet need, Roivant and its subsidiaries aim to create value for both patients and investors. The progress of mosliciguat is a key part of this narrative, representing a significant late-stage asset in Roivant's pipeline. As the PHocus trial moves toward its 2026 data readout, the entire PH-ILD community will be watching, hopeful that this accelerated progress will soon translate into a much-needed clinical breakthrough.